Gallamine triethiodide, designated Pyrolaxon veterinary-grade active pharmaceutical ingredient, is the triethiodide salt of 1,2,3-tris(2-triethylammoniumethoxy)benzene. It is supplied as a white to off-white crystalline powder with CAS 65-29-2, molecular formula C30H60I3N3O3, and molar mass 891.53 g/mol. The product model covers the API form for tablets, injections, capsules, powders, granules, premix, and solutions, not finished dosage forms. As a quaternary ammonium neuromuscular blocking agent, the cation remains ionised across the gastrointestinal pH range, limiting oral absorption and defining the operational boundary between injectable and oral solid presentations. The powder is freely soluble in water; a 2% w/v solution is clear and colourless when freshly prepared under nitrogen. The material is hygroscopic and requires moisture-controlled storage below 60% relative humidity.

Pharmacopoeial Specification Ranges and Physicochemical Limits

Release documentation for this material is typically structured around the current monograph for gallamine triethiodide where a pharmacopoeial monograph exists, supplemented by ICH Q7 and VICH GL18 requirements. Identification is confirmed by infrared absorption spectrophotometry against a qualified reference standard and by iodide precipitation after acidified hydrolysis. Assay on the dried basis is determined by non-aqueous titration or ion-pair HPLC, with a release target of 98.0–101.0%. Loss on drying at 105°C is controlled because the triethiodide salt is hygroscopic; production-scale batches released to solid dosage form manufacturers typically show values below 0.5% when stored in sealed aluminium-foil bags. Related substances are monitored by HPLC area normalisation, with total impurities targeted at ≤0.5% and any single impurity at ≤0.1%. Residual solvents are controlled under ICH Q3C, elemental impurities under ICH Q3D, and the iodide counterion is confirmed by ion chromatography. Particle size distribution is not fixed in the monograph but is matched to the intended process.

Because the release profile is matched to the intended dosage form rather than fixed by a single monograph, veterinary manufacturers should request the specific certificate of analysis for the planned process. The current edition of the applicable pharmacopoeial monograph remains definitive where a monograph exists.

Dry blending of gallamine triethiodide for powders, granules, and premix presentations is constrained by the compound’s hygroscopicity and electrostatic behaviour. Production-scale ribbon blenders and high-shear granulators should be operated with jacket relative humidity below 40%; extended exposure above 60% RH causes particle agglomeration and variable bulk density. For tablet compression, the API is pre-sieved through a 500 µm security screen and pre-blended with a direct-compression diluent before lubrication with magnesium stearate at 0.25–0.5% w/w. Higher lubricant levels reduce tablet hardness because the hydrophobic stearate coats the water-soluble API and limits interparticulate bonding. Capsule filling of low-dose strengths requires geometric dilution or trituration because the quaternary ammonium salt has poor flow and high pharmacological potency; powder segregation in gravity-fed capsule machines is minimised by matching the API D50 to the excipient D50 within 50 µm. Wet granulation with aqueous binders is less preferred because the triethiodide salt can partially dissolve and recrystallise as needle-shaped particles during drying, increasing die-fill variability and friability.

For premix and granule presentations intended for incorporation into feed or oral dosage, the API is first dispersed in a non-hygroscopic carrier such as anhydrous lactose or spray-dried mannitol. A two-stage mixing sequence is used: a low-shear tumble blender creates a 1:10 triturate, then a high-shear mixer distributes the triturate to the final blend. The final blend is sampled from 10 locations at 3 depths per location to confirm content uniformity; acceptance limits for the API in the blend are 90.0–110.0% of target with an RSD of ≤5.0%. Because gallamine triethiodide is highly water-soluble but poorly absorbed orally, the dissolution test for solid presentations is not a simple surrogate for bioavailability; it is used only as a quality control for release consistency. For low-dose granules, particle size is controlled by passing the final blend through a 1000 µm mesh and rejecting oversized agglomerates.

What Limits Direct Compaction of Gallamine Triethiodide Granules in Multi-Component Premixes?

The limiting factor is the competition between the API’s water uptake and the mechanical integrity of the granule. Dry granulation by roller compaction is preferred over aqueous wet granulation; a practical starting range on a 200 mm roller compactor is 20–50 kN roll force with 6–10% fines recirculation, though published data for this specific configuration is limited and must be confirmed by design of experiments. Multi-component premixes containing reducing sugars or aldehyde-bearing excipients are avoided because the quaternary ammonium iodide can discolour under moist heat, and the resulting chromophores are difficult to remove by final sieving. A starting formulation with microcrystalline cellulose and pregelatinised starch, plus sodium starch glycolate at 2–4% as disintegrant, is typically evaluated first. If a filled capsule or tablet exhibits capping, the roll force is reduced and the preblend is allowed to equilibrate at 25°C and 30% RH before final compression.

Clinical use of gallamine triethiodide is confined to procedures where controlled positive-pressure ventilation is available, because the non-depolarising block affects respiratory muscles before recovery of laryngeal reflexes. In equine and canine protocols, the API is administered intravenously as a diluted solution; published veterinary formularies describe dose titration under inhalant anaesthesia, but exact doses are species-specific and require individual veterinary oversight. The oral presentations named in the product range—tablets, capsules, powders, granules, and premix—are not used for acute neuromuscular blockade in conscious animals because the quaternary ammonium structure produces negligible oral bioavailability; these presentations are intended for regulated compounding, export supply, or research use where the API is further processed. For injectable solutions, the API is dissolved in water for injection and the solution is filtered through 0.22 µm PVDF membranes; filter adsorption is expected to be low because the molecule is highly hydrophilic, but filter validation is required for concentrations below 1 mg/mL.

When a Veterinary Injectable Is Subjected to Moist-Heat Sterilisation at 121°C

When a veterinary injectable is subjected to moist-heat sterilisation at 121°C, the formulation must hold the triethiodide salt in an acidic, oxygen-depleted environment. Aqueous solutions are typically adjusted to pH 4.0–5.0 with dilute hydrochloric acid or citrate buffer before autoclaving; the acidic pH reduces iodide oxidation and the formation of free iodine that stains elastomeric closures. The solution is filled under nitrogen into Type I borosilicate vials with chlorobutyl rubber closures; headspace oxygen is maintained below 1.0% to retard oxidative yellowing. A standard overkill cycle at 121°C for 15 min provides an F0 of 15 min, but published forced-degradation data for this specific configuration is limited, so the cycle should be bracketed during validation rather than assumed from human drug product files. Post-sterilisation, subvisible particulate matter is controlled by compendial light obscuration tests such as USP <788> or Ph. Eur. 2.9.19; the acceptance limit for containers of not more than 100 mL is 6000 particles/container at 10 µm and 600 particles/container at 25 µm. Container-closure integrity is challenged by dye ingress or vacuum decay methods in accordance with USP <1207>.

Where terminal sterilisation is not supported by stability data, aseptic filtration through two validated 0.22 µm PVDF or polyethersulfone filters in series is used. The filling line is installed in an EU GMP Grade A zone with Grade B background, and filter integrity is confirmed by bubble point or water intrusion testing before and after filling. The same pH and nitrogen overlay controls apply because oxidative yellowing is also a time-dependent degradation pathway at room temperature. For large-volume parenteral preparations, container headspace should remain below 2.0% oxygen, and the fill volume is adjusted to compensate for stopper moisture vapour transmission during shelf life. Routine release of injectable solutions includes pH, osmolarity, assay, related substances, sterility, bacterial endotoxins, and subvisible particulate matter. Osmolarity is adjusted with sodium chloride to 280–320 mOsmol/kg; dextrose-containing diluents are avoided unless compatibility data exist because reducing sugars can promote iodide discoloration. The pH after autoclaving is monitored, and a shift of more than 0.5 pH units triggers rejection because it indicates buffer failure or stopper leaching.

Oxidative Headspace Conditions Accelerate Iodide Discoloration in the Triethiodide Salt

Chromatographic purity methods for gallamine triethiodide require ion-pairing or HILIC separation because the molecule is highly polar and lacks a strong UV chromophore above 254 nm; refractive index detection or charged aerosol detection is preferred. The iodide counterion is monitored by ion chromatography, with a system precision target of RSD ≤2.0% for six replicate injections. Potentiometric titration of iodide with silver nitrate can be used as a specific assay for the counterion, with a stoichiometric endpoint corresponding to three iodide equivalents per molecule. Release data should not rely solely on low-wavelength UV detection because quaternary ammonium compounds and their excipients can produce interfering peaks. Analytical method validation for assay and related substances follows ICH Q2(R1). Specificity is demonstrated by forced degradation under acid, base, peroxide, heat, and light; the main degradation product in acidic aqueous solution is free iodine, which is not detected by the API assay and must be measured separately. Linearity is assessed over a range of 80–120% of the nominal test concentration, with a correlation coefficient target of ≥0.999. Accuracy is determined by spiked recovery experiments in pooled formulation matrix, with an acceptance range of 98.0–102.0% for assay and 80–120% for individual impurities.

Differences from other non-depolarising neuromuscular blockers arise from gallamine’s vagolytic activity and renal elimination. In comparison with atracurium, which undergoes Hofmann elimination and ester hydrolysis largely independent of renal function, gallamine relies on glomerular filtration; duration of action therefore extends in animals with reduced renal clearance. Unlike pancuronium, gallamine has a similar vagolytic tendency but is generally shorter acting in species where comparative data exist. Unlike rocuronium, it lacks the aminosteroid substitution pattern and the associated hepatic uptake. These differences make the product less interchangeable in renal-compromised patients and protocols requiring predictable recovery.

Compared with halide salts such as bromide, the triethiodide salt carries a higher counterion mass and different hygroscopicity. This affects potency calculations: the active moiety concentration must be expressed on the basis of the gallamine cation rather than the whole salt. In a 10 mg/mL injectable solution, a chloride or bromide equivalent would require a different molar mass correction; formulators must confirm whether the label strength is expressed as the triethiodide salt or as the gallamine cation. The distinction is also relevant when substituting between pharmacopoeial substances from different suppliers.

Because gallamine triethiodide is a pharmacologically active quaternary ammonium salt, open handling is performed under local exhaust ventilation or in a downflow booth. The API is not considered a cytotoxin, but a widely harmonised occupational exposure limit for neuromuscular blocking agents is not published; therefore containment is based on pharmacological activity and the supplier’s material safety data. Cross-contamination in multi-product facilities is controlled by using dedicated scoops, disposable liners, and validated cleaning cycles with an aqueous rinse followed by an organic wipe. Swab limits are derived from the permitted daily exposure and the worst-case veterinary target species mass. Analytical cleaning verification should target both the gallamine cation and iodide to detect residues that may not be visible after drying.

Stability protocols for the unformulated API follow ICH Q1A storage at 25°C/60% RH and accelerated 40°C/75% RH. Because the triethiodide salt is hygroscopic, the accelerated condition often shows greater discoloration than the long-term condition; retest data should be collected at 3, 6, 9, 12, 18, 24, and 36 months with tight container closure. A retest period is assigned only when the batch remains within specification at the end of the intended storage period; the supplier’s certificate of analysis includes the retest date. Storage of the API is at controlled room temperature, below 25°C and 60% RH. Opened containers are re-sealed under nitrogen because the triethiodide salt darkens on exposure to light and moisture. The product is manufactured under ICH Q7 for active pharmaceutical ingredients, and documentation supports veterinary marketing authorisation dossiers under VICH GL18. Batch release for injectable-grade material can be provided with a bacterial endotoxin limit of <0.05 EU/mg where specified; oral-grade material is controlled to a total aerobic microbial count of ≤1000 CFU/g and total yeast and mould count of ≤100 CFU/g. The difference between veterinary and human grades lies in regulatory documentation and residue risk assessment rather than in molecular structure; the same quaternary ammonium cation is supplied, but the veterinary-grade supply chain is separated to prevent cross-contamination with human-only excipient standards. No single grade of the API is suitable for all seven presentations; sterile injectable manufacturing requires endotoxin control and particle size may differ from solid oral or premix grades.